http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2023, Vol. 32 ›› Issue (6): 473-477.DOI: 10.5246/jcps.2023.06.040

• Original articles • Previous Articles     Next Articles

Cidofovir inhibits human adenovirus type 55 infection in vitro

Wenbo Wang1, Mengke Wang2,3, Zonghai Hu2, Jie Xiong2, Yuan Liu2,*()   

  1. 1 Department of Disease Control and Prevention, General Hospital of Western Theater Command, Chengdu 610083, Sichuan, China
    2 Department of Clinical Laboratory, General Hospital of Western Theater Command, Chengdu 610083, Sichuan, China
    3 College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan, China
  • Received:2022-12-23 Revised:2023-01-06 Accepted:2023-01-23 Online:2023-07-01 Published:2023-07-01
  • Contact: Yuan Liu

Abstract:

Human adenovirus type 55 (HAdV-55) can usually cause acute respiratory diseases. Unfortunately, there is no available specific antiviral drug. In the present study, 14 nucleotide analogs were screened for their anti-HAdV-55 activities in vitro. The results suggested that cidofovir could inhibit HAdV-55 infection in HEp-2 cells, providing strong evidence for further research on treating HAdV-55 infection.

Key words: Cidofovir, Adefovir, Tenofovir, Adenovirus, HAdV-55

Supporting: /attached/file/20230702/20230702111129_565.pdf